American Journal of Epidemiology Advance Access originally published online on January 23, 2008
American Journal of Epidemiology 2008 167(6):692-700; doi:10.1093/aje/kwm362
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL CONTRIBUTIONS |
Incidence of Dementia in Long-term Hormone Users
1 Department of Clinical Analysis, Kaiser Permanente Southern California, Pasadena, CA
2 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA
3 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA
4 Department of Research and Development, eHarmony, Pasadena, CA
5 Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA
Correspondence to Dr. Valerie Crooks, Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Floor, Pasadena, CA 91101 (e-mail: Valerie.c.crooks{at}kp.org).
Received for publication June 20, 2007. Accepted for publication November 9, 2007.
Results from epidemiologic studies of postmenopausal hormone use and dementia have been conflicting. Investigators from the Women's Health Initiative Memory Study reported that the incidence of dementia in women aged 
65 years assigned to hormone use was increased. Here the authors report results from a prospective cohort study of 2,906 dementia-free women (1,519 hormone users and 1,387 hormone nonusers) aged 75 years who were recruited from a Southern California health plan in 1999 and followed through 2003. Cognitive status was assessed annually using the Telephone Interview of Cognitive Status–modified, supplemented by the Telephone Dementia Questionnaire and medical record review. The mean self-reported age at initiation of hormone use was 48.3 years for users of estrogen alone (n = 1,072) and 54.9 years for users of estrogen plus progestin (n = 447); self-reported mean durations of hormone use were 30.5 years and 23.2 years, respectively. There were 283 incident dementia cases identified during follow-up. After adjustment for age, education, and medical history, hazard ratios for incident dementia were 1.34 (95% confidence interval: 0.95, 1.89) in estrogen/progestin users and 1.23 (95% confidence interval: 0.94, 1.59) in estrogen users. These findings do not provide support for an effect of estrogen or estrogen/progestin use in preventing dementia.
Alzheimer disease; dementia; hormone replacement therapy
Abbreviations: CI, confidence interval; SD, standard deviation; TDQ, Telephone Dementia Questionnaire; TICSm, Telephone Interview of Cognitive Status–modified
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Ryan, I. Carriere, J. Scali, J. F. Dartigues, C. Tzourio, M. Poncet, K. Ritchie, and M. L. Ancelin Characteristics of hormone therapy, cognitive function, and dementia: The prospective 3C Study Neurology, November 24, 2009; 73(21): 1729 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Does Hormone Therapy Prevent Postmenopausal Dementia? Journal Watch Women's Health, May 22, 2008; 2008(522): 5 - 5. [Full Text]
|
|